检验医学与临床2017，Vol.14Issue(18)：2655-2657,2661,4.DOI:10.3969/j.issn.1672-9455.2017.18.001
异基因造血干细胞移植治疗骨髓增生异常综合征20例临床分析
Clinical analysis of allogeneic hematopoietic stem cell transplantation in the treatment of myelodysplastic syndrome in 20 cases
摘要
Abstract
Objective To analyse and evaluate the clinical effects of allogeneic hematopoietic stem cell transplantation (AlloHSCT) for patients with myelodysplastic syndrome (MDS).Methods From November 2009 to March 2015,a total of 20 patients with (primary diagnosis) MDS were treated with Allo-HSCT in the Hematopoietic Stem Cell Transplantation Center of the First Affiliated Hospital of Chongqing Medical University,including 8 females and 12 males with the median age 48 (16-62) years old.Results The hematopoietic system were successfully reconstructed in 18 cases,and the other 2 cases had not obtained hematopoietic reconstitution.The median time of absolute neutrophil count(ANC) ≥0.5 × 109/L and PLT≥20 × 109/L was 10.5 (8-25) d and 13.5(10-31) d respectively.Three cases developed acute graft-versus-host disease (aGVHD) and 9 cases developed chronic GVHD (cGVHD).All patients were followed up until March 30,2015.The median follow-up time was 12.8(1.1-60.2) mon.13 cases survived with disease-free,and the other 7 cases were all died,in which 1 case died of recurrence and the other 6 cases died of transplant related complications (TRCs).By the end of the follow-up date,the overall survival (OS) and disease-free survival (DFS) rate were both 65.0％.The accumulated relapse rate (RR) was 5.0％,and the transplant-related mortality (TRM) and nonrelapse mortality (NRM) rates were both 30.0％.Conclusion Allo-HSCT is an effective method for the treatment of intermediaterisk and high-risk young patients with MDS,and should be the first choice of treatment and performed as early as possible.关键词
异基因造血干细胞移植/骨髓增生异常综合征/地西他滨Key words
allogeneic hematopoietic stem cell transplantation/myelodysplastic syndrome/decitabine引用本文复制引用
但春莉,刘林,王利,张端众,肖青,张红宾,唐晓琼,王建渝,王欣,杨泽松,陈建斌..异基因造血干细胞移植治疗骨髓增生异常综合征20例临床分析[J].检验医学与临床,2017,14(18):2655-2657,2661,4.基金项目
国家自然科学基金资助项目(81250034) （81250034）
重庆市卫生和计划生育委员会资助项目(2013-2-023). （2013-2-023）
